Cargando…
Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor
BACKGROUND: Mutations in POLE /POLD1 proofreading domain can cause deficiencies in DNA repair, conferring ultramutated cancer phenotypes. Preliminary clinical studies have revealed an association between POLE/POLD1 mutations and beneficial clinical outcomes to immune checkpoint inhibitor (ICI) thera...
Autores principales: | He, Junjun, Ouyang, Wei, Zhao, Wugan, Shao, Lin, Li, Bing, Liu, Bihao, Wang, Dejuan, Han-Zhang, Han, Zhang, Zhou, Shao, Liang, Li, Wencai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867935/ https://www.ncbi.nlm.nih.gov/pubmed/33569431 http://dx.doi.org/10.21037/atm-20-7553 |
Ejemplares similares
-
Role of POLE and POLD1 in familial cancer
por: Mur, Pilar, et al.
Publicado: (2020) -
POLE/POLD1 mutation and tumor immunotherapy
por: Ma, Xiaoting, et al.
Publicado: (2022) -
POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
por: Chen, Yan‐Xing, et al.
Publicado: (2021) -
Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma
por: Zhu, Mingyu, et al.
Publicado: (2022) -
Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1
por: Mur, Pilar, et al.
Publicado: (2023)